References

Bladder cancer: A review

10.1001/jama.2020.17598 · ExternalCitation · doi-reference

Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer

10.1002/advs.202400156 · ExternalCitation · doi-reference

Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

10.1002/cam4.6680 · ExternalCitation · doi-reference

Psychological distress in bladder cancer patients: A systematic review

10.1002/cam4.70345 · ExternalCitation · doi-reference

Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer

10.1016/j.drup.2024.101059 · ExternalCitation · doi-reference

European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)

10.1016/j.eururo.2021.08.010 · ExternalCitation · doi-reference

A comprehensive insight into plant-derived extracts/bioactives: Exploring their antimicrobial mechanisms and potential for high-performance food applications

10.1016/j.fbio.2024.104035 · ExternalCitation · doi-reference

Emerging opportunities or paradoxes: Assessing the effect of digital technology adoption on corporate carbon performance

10.1016/j.jenvman.2025.126399 · ExternalCitation · doi-reference

Cancer drug indication approvals in China and the United States: A comparison of approval times and clinical benefit, 2001-2020

10.1016/j.lanwpc.2024.101055 · ExternalCitation · doi-reference

Recent trends in the micro-encapsulation of plant-derived compounds and their specific application in meat as antioxidants and antimicrobials

10.1016/j.meatsci.2022.108842 · ExternalCitation · doi-reference

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial

10.1016/s0140-6736(17)33297-x · ExternalCitation · doi-reference

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial

10.1016/s1470-2045(24)00178-5 · ExternalCitation · doi-reference

Plant-derived nanovesicles: A promising frontier in tissue repair and antiaging

10.1021/acs.jafc.5c01547 · ExternalCitation · doi-reference

World-first therapy using donor cells sends autoimmune diseases into remission

10.1038/d41586-024-03209-4 · ExternalCitation · doi-reference

Heightened IDO1 levels predict Bacillus Calmette-Guèrin failure in high-risk non-muscle-invasive bladder cancer patients

10.1038/s41420-025-02489-7 · ExternalCitation · doi-reference

Bladder cancer

10.1038/s41572-023-00468-9 · ExternalCitation · doi-reference

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

10.1038/s41586-022-05140-y · ExternalCitation · doi-reference

Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

10.1038/s41746-025-01560-y · ExternalCitation · doi-reference

Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors

10.1056/nejme058127 · ExternalCitation · doi-reference

Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinom

10.1056/nejmoa2308849 · ExternalCitation · doi-reference

Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma

10.1056/nejmoa2309863 · ExternalCitation · doi-reference

ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer

10.1056/nejmoa2511885 · ExternalCitation · doi-reference

Quality of life in non-muscle-invasive bladder cancer survivors: A systematic review

10.1097/ncc.0000000000000606 · ExternalCitation · doi-reference

Review of BCG immunotherapy for bladder cancer

10.1128/cmr.00194-23 · ExternalCitation · doi-reference

Advances in diagnosis and treatment of bladder cancer

10.1136/bmj-2023-076743 · ExternalCitation · doi-reference

Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial

10.1158/1078-0432.ccr-22-2158 · ExternalCitation · doi-reference

FDA approval summary: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

10.1158/1078-0432.ccr-24-1393 · ExternalCitation · doi-reference

Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

10.1158/1538-7445.am2020-5581 · ExternalCitation · doi-reference

Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021

10.1186/s40779-024-00569-w · ExternalCitation · doi-reference

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study

10.1200/jco.18.01148 · ExternalCitation · doi-reference

Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: Results from a tertiary center in the contemporary BCG-shortage era

10.21037/tau-22-772 · ExternalCitation · doi-reference

A narrative review of management of muscle-invasive bladder cancer perioperative period: Will continuous and combined treatment be the new trend

10.21037/tau-23-494 · ExternalCitation · doi-reference

The BCG shortage

10.3233/blc-179018 · ExternalCitation · doi-reference

Plant-derived extracellular vesicles: An alternative and complementary therapeutic approach for genitourinary tumors

10.3389/fcell.2025.1695636 · ExternalCitation · doi-reference

Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: A comparative analysis of efficacy and safety in muscle-invasive bladder cancer

10.3389/fimmu.2025.1549647 · ExternalCitation · doi-reference

CAR-T cell therapies in autoimmune rheumatic diseases: A brief report on the clinical trial landscape, current status, and future perspectives

10.3389/fimmu.2025.1630569 · ExternalCitation · doi-reference

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

10.3389/fonc.2022.907377 · ExternalCitation · doi-reference

The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence

10.3389/fonc.2024.1364702 · ExternalCitation · doi-reference

Plant-derived exosome-like nanoparticles for biomedical applications and regenerative therapy

10.3390/biomedicines11041053 · ExternalCitation · doi-reference

BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer

10.3390/curroncol31020079 · ExternalCitation · doi-reference

Bladder cancer: Current challenges and future directions [review

10.3390/medicina57080749 · ExternalCitation · doi-reference

Comparative analysis of machine learning methods and a physical model for shallow landslide risk modeling

10.3390/su15010006 · ExternalCitation · doi-reference

Wearable technology in healthcare: Opportunities, challenges, and future directions

10.47852/bonviewswt52025578 · ExternalCitation · doi-reference

Switching on smart care: The ascendancy of wireless technologies in continuous health surveillance

10.47852/bonviewswt52026811 · ExternalCitation · doi-reference